Clinical Trials Logo

Drug-eluting Stents clinical trials

View clinical trials related to Drug-eluting Stents.

Filter by:

NCT ID: NCT05692882 Not yet recruiting - Drug-Eluting Stents Clinical Trials

A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The primary objective of this trial is to evaluate the long-term safety and efficacy of the NOVA intracranial drug-eluting stent system in "real world" patients with intracranial atherosclerotic stenosis.

NCT ID: NCT05677711 Active, not recruiting - Clinical trials for Coronary Artery Disease

Safety and Efficacy of the Ultimaster Stent

Start date: July 20, 2021
Phase:
Study type: Observational [Patient Registry]

Durable polymer was considered to be the cause of a chronic inflammatory response that leadas to impaired endothelialization of the stent strut and subsequently increases the risk of stent thrombosis. Ultimaster stent (Ultimaster, Terumo Corporation, Tokyo, Japan) are thin strut, silorimus-eluting, biodegradable copolymer to completely degrade over 3-4 months.

NCT ID: NCT04949516 Completed - Clinical trials for Acute Coronary Syndrome

Mono Antiplatelet and Colchicine Therapy

MACT
Start date: June 15, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of aspirin-free, P2Y12 inhibitor single antiplatelet and colchicine treatment in patients with acute coronary syndrome treated with drug-eluting stents.

NCT ID: NCT04778969 Not yet recruiting - Clinical trials for Coronary Artery Disease

Kor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance Database

Start date: April 1, 2021
Phase:
Study type: Observational

Current Status and Prognosis of Coronary artery disease patients treated with coronary intervention - Analysis of the Korean Nationwide Health Insurance Database

NCT ID: NCT04744571 Enrolling by invitation - Clinical trials for Coronary Artery Disease

Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions

Start date: February 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of drug-coated balloon angioplasty for the treatment of chronic total occlusions patients with chronic total occlusion (CTO) lesion.

NCT ID: NCT04738344 Withdrawn - Clinical trials for Coronary Artery Disease

Very Long Versus Overlapping Stents in Long Coronary Lesions

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This study is performed to compare the angiographic and clinical outcomes of the use of single long stent versus overlapping stents in the treatment of long coronary lesions in patients with chronic coronary syndrome.

NCT ID: NCT04150016 Recruiting - Clinical trials for Percutaneous Coronary Intervention

In-stent Repair and Vessel Reaction of STEMI Patients With OCT

Start date: March 8, 2019
Phase: N/A
Study type: Interventional

This study is a prospective, multi-center, non-inferior, randomized controlled clinical trial, aims to use optical Coherence tomography to observe the the early- and mid-stage vessel repair and neointimal proliferation. And to assess the safety and effectiveness of the Firehawk™ sirolimus target-eluting coronary stent system with abluminal grooves containing a biodegradable polymer (Firehawk™) comparing the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ST-elevation myocardial infarction (STEMI).

NCT ID: NCT03783351 Recruiting - Clinical trials for Acute Coronary Syndrome

Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)

Start date: May 27, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to assess the efficacy and safety of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel in non-carriers of a CYP2C19*2 or *3 allele and ticagrelor in carriers of a CYP2C19*2 or *3 allele in patients treated with new generation drug eluting stents.

NCT ID: NCT03197298 Completed - Clinical trials for Acute Coronary Syndrome

Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome

CHANGE DAPT
Start date: December 21, 2012
Phase: N/A
Study type: Observational [Patient Registry]

Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin). This change is based on studies that showed benefits of ticagrelor. However, study participants were only partly treated by percutaneous coronary intervention (PCI). In patients who were treated by PCI, this was generally performed using of bare metal or first-generation drug-eluting stents (DES). CHANGE DAPT is an investigator-initiated, prospective, single centre registry, in which we evaluate the impact of the guideline suggested change in the primary DAPT regimen (from clopidogrel to ticagrelor) on 1-year clinical outcome in ACS patients treated by PCI with newer-generation DES in the Thoraxcentrum Twente.

NCT ID: NCT03180931 Completed - Clinical trials for Tomography, Optical Coherence

Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis

INVEST
Start date: December 2, 2016
Phase: N/A
Study type: Observational [Patient Registry]

Bioresorbable vascular scaffold (BVS, ABSORB BVS1.1, Abbott Vascular) has been approved (CE mark) and is used in daily clinical practice. While recent randomized controlled trials comparing BVS versus metallic drug-eluting stent showed higher risk of definite or probable device thrombosis after BVS implantation, the causes underlying thrombotic events occurring beyond one year after scaffold implantation remain unclear and require investigation in an independent manner. The INVEST registry is a world-wide, multi-center, observational, retrospective, investigator-initiated registry, which will include any patients who suffered from very late (>1 year) scaffold thrombosis, underwent optical coherence tomography (OCT) at the time of thrombosis and provided informed consent for the further use of their health related data for this registry.